🔴 Veracyte is trading 26.1% down in pre-market after lowering testing revenue guidance

Veracyte is trading at $38.80, down 26.12% in pre-market as its earnings outlook appears to be the main catalyst.

• Q3 revenue was $151.8 million, up 15% year over year; adjusted EPS was $0.51.
• 2026 revenue guidance narrowed to $590 million–$593 million from $590 million–$596 million; testing revenue guidance was lowered, and Decipher Prostate volume was below expectations.
• Veracyte announced a $100 million repurchase program, but it has not offset investor concern about the outlook.